Inflammatory and endothelial markers in women with polycystic ovary syndrome - PubMed (original) (raw)
Inflammatory and endothelial markers in women with polycystic ovary syndrome
E Diamanti-Kandarakis et al. Eur J Clin Invest. 2006 Oct.
Abstract
Background: Women with polycystic ovary syndrome (PCOS) carry a pattern of cardiovascular risk factors. Endothelial dysfunction and chronic inflammation are early findings in the atherosclerotic process. The purpose of the study was to investigate the coexistence of active inflammation markers and endothelial dysfunction in young women with PCOS, and their relationship with metabolic and hormonal abnormalities of the syndrome.
Materials and methods: Twenty-five young women with PCOS and 25 controls of similar age and body mass index (BMI) were studied. Endothelial function was assessed by flow-mediated dilatation (FMD) on the brachial artery and smooth muscle cells injury was excluded by nitrate-induced dilatation (NID). Plasma levels of endothelin-1 (ET-1), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) and high sensitivity C-reactive protein (hsCRP) were measured. Hormonal and metabolic profiles were determined in both groups.
Results: Flow-mediated dilatation (FMD) was statistically lower in PCOS (P < 0.001), whereas nitrate-induced dilatation (NID) was similar within the two groups. Polycystic ovary syndrome (PCOS) had statistically higher levels of ET-1 (P = 0.03), sICAM-1 (P = 0.01), sVCAM-1 (P = 0.02) and hsCRP (P = 0.01). Furthermore FMD was statistically higher in PCOS population with hsCRP 1 mg L(-1) when compared with PCOS population with hsCRP > 1 mg L(-1) (P = 0.02). Flow-mediated dilatation (FMD) was negatively related to hsCRP (r = -0.512, P = 0.015); ET-1 was positively related to free androgen index (r = 0.27, P = 0.05) and negatively to sex hormone-binding globulin (r = -0.465, P = 0.022); sVCAM-1 was positively related to total testosterone (r = 0.431, P = 0.036); hsCRP was positively related to BMI (r = 0.647, P = 0.001), and negatively related to FMD (r = -0.512, P = 0.015), quantitative insulin sensitivity check index (QUICKI) (r = -0.499, P = 0.018), and MATSUDA index (r = -0.445, P = 0.038).
Conclusions: The present study demonstrates that endothelial dysfunction coexists and is influenced by the presence of increased serum levels of inflammation and endothelial activation markers in young women with PCOS. These parameters appear to be interrelated with hyperandrogenaemia in this insulin-resistant population.
Similar articles
- Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D. Diamanti-Kandarakis E, et al. Hum Reprod. 2006 Jun;21(6):1426-31. doi: 10.1093/humrep/del003. Epub 2006 Feb 23. Hum Reprod. 2006. PMID: 16497699 Clinical Trial. - Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome.
Brinkworth GD, Noakes M, Moran LJ, Norman R, Clifton PM. Brinkworth GD, et al. BJOG. 2006 Nov;113(11):1308-14. doi: 10.1111/j.1471-0528.2006.01090.x. BJOG. 2006. PMID: 17059392 - Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies.
Sprung VS, Atkinson G, Cuthbertson DJ, Pugh CJ, Aziz N, Green DJ, Cable NT, Jones H. Sprung VS, et al. Clin Endocrinol (Oxf). 2013 Mar;78(3):438-46. doi: 10.1111/j.1365-2265.2012.04490.x. Clin Endocrinol (Oxf). 2013. PMID: 22775449 Review. - Biomarkers of Endothelial Dysfunction in Women With Polycystic Ovary Syndrome.
Dambala K, Paschou SA, Michopoulos A, Siasos G, Goulis DG, Vavilis D, Tarlatzis BC. Dambala K, et al. Angiology. 2019 Oct;70(9):797-801. doi: 10.1177/0003319719840091. Epub 2019 Apr 10. Angiology. 2019. PMID: 30969784 Review.
Cited by
- Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review.
Iervolino M, Lepore E, Forte G, Laganà AS, Buzzaccarini G, Unfer V. Iervolino M, et al. Nutrients. 2021 May 15;13(5):1677. doi: 10.3390/nu13051677. Nutrients. 2021. PMID: 34063339 Free PMC article. Review. - Exploring the Pharmacological Mechanism of Quercetin-Resveratrol Combination for Polycystic Ovary Syndrome: A Systematic Pharmacological Strategy-Based Research.
Yang K, Zeng L, Bao T, Long Z, Jin B. Yang K, et al. Sci Rep. 2019 Dec 5;9(1):18420. doi: 10.1038/s41598-019-54408-3. Sci Rep. 2019. PMID: 31804513 Free PMC article. - Prevention of Coronary Artery Disease in Women.
Liu E, Bigeh A, Ledingham L, Mehta L. Liu E, et al. Curr Cardiol Rep. 2022 Aug;24(8):1041-1048. doi: 10.1007/s11886-022-01721-5. Epub 2022 Jun 14. Curr Cardiol Rep. 2022. PMID: 35699818 Review. - The monocyte counts to HDL cholesterol ratio in obese and lean patients with polycystic ovary syndrome.
Usta A, Avci E, Bulbul CB, Kadi H, Adali E. Usta A, et al. Reprod Biol Endocrinol. 2018 Apr 10;16(1):34. doi: 10.1186/s12958-018-0351-0. Reprod Biol Endocrinol. 2018. PMID: 29631598 Free PMC article. - Cardiovascular risk factors and events in women with androgen excess.
Macut D, Antić IB, Bjekić-Macut J. Macut D, et al. J Endocrinol Invest. 2015 Mar;38(3):295-301. doi: 10.1007/s40618-014-0215-1. Epub 2014 Nov 29. J Endocrinol Invest. 2015. PMID: 25432327 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials